Economic Issues of Chronic Kidney Disease and End-Stage Renal Disease.
Economic Issues of Chronic Kidney Disease and End-Stage Renal Disease.
复制标题
慢性肾病和终末期肾病的经济问题。
DOI：
--
复制
发表时间：
2019
影响因子：
--
通讯作者：
T. Naganuma
中科院分区：
文献类型：
--
作者：
Y. Takemoto;T. Naganuma
背景
随着全球经济的增长，全世界接受肾脏替代治疗（如血液透析）的患者数量每年增加6-7%。因此，治疗进展为终末期肾病（ESRD）的慢性肾病（CKD）以及肾脏替代疗法的医疗费用已成为主要问题。
总结
据报道，在美国，CKD患者每年的医疗费用约为20，000美元，CKD患者的总医疗费用高于ESRD患者[1]。在本研究中，我们发现，与美国和欧洲相比，日本肾脏替代治疗（RRT）的医疗费用是合理的。关键信息：日本RRT的医疗费用合理，在日本不是主要问题。
BACKGROUND
With the growth in the global economy, the number of patients worldwide undergoing renal replacement therapy such as hemodialysis is increasing by 6-7% annually. Accordingly, medical costs for the treatment of chronic kidney disease (CKD) progressing to end-stage renal disease (ESRD) as well as for renal replacement therapy have become a major issue.
SUMMARY
It has been reported that in the United States, the annual medical cost for a patient with CKD is approximately USD 20,000, and that the total medical cost for a CKD patient is higher than that of an ESRD patient [1]. In the present study, we found that the medical costs for renal replacement therapy (RRT) in Japan are reasonable compared to those in the United States and Europe. Key Messages: The medical costs for RRT in Japan are reasonable and are not a major issue in Japan.